Dr.LeslieOBGYN said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Thank you — that is the clearest version of this I have read, and I have read a lot of them.

Clinical perspective, offered as context rather than as advice. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Dr.RaviCardio said:

I want to add the drug interaction perspective on the pharmacology.

I am going to disagree with the direction of travel here. The thread has converged on the tidiest answer rather than the best-supported one, and those are not the same thing.

Happy to go further on any of that.

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

That is the short version; the long version is somebody else's post.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Carry on.